




# The Jefferson Manual for Neurocritical Care

Jack I. Jallo  
Jacqueline S. Urtecho









# The Jefferson Manual for Neurocritical Care

**Jack I. Jallo, MD, PhD**

Professor and Vice-Chair for Academic Services;

Director

Division of Neurotrauma and Critical Care

Department of Neurological Surgery

Sidney Kimmel Medical College

Thomas Jefferson University

Philadelphia, Pennsylvania, USA

**Jacqueline S. Urtecho, MD**

Assistant Professor of Neurology and Neurological Surgery

Department of Neurological Surgery

Division of Neurotrauma and Critical Care

Sidney Kimmel Medical College

Thomas Jefferson University

Philadelphia, Pennsylvania, USA

78 illustrations

Thieme

New York • Stuttgart • Delhi • Rio de Janeiro

Library of Congress Cataloging-in-Publication Data  
is available from the publisher.

**Important note:** Medicine is an ever-changing science undergoing continual development. Research and clinical experience are continually expanding our knowledge, in particular our knowledge of proper treatment and drug therapy. Insofar as this book mentions any dosage or application, readers may rest assured that the authors, editors, and publishers have made every effort to ensure that such references are in accordance with **the state of knowledge at the time of production of the book.**

Nevertheless, this does not involve, imply, or express any guarantee or responsibility on the part of the publishers in respect to any dosage instructions and forms of applications stated in the book. **Every user is requested to examine carefully** the manufacturers' leaflets accompanying each drug and to check, if necessary in consultation with a physician or specialist, whether the dosage schedules mentioned therein or the contraindications stated by the manufacturers differ from the statements made in the present book. Such examination is particularly important with drugs that are either rarely used or have been newly released on the market. Every dosage schedule or every form of application used is entirely at the user's own risk and responsibility. The authors and publishers request every user to report to the publishers any discrepancies or inaccuracies noticed. If errors in this work are found after publication, errata will be posted at [www.thieme.com](http://www.thieme.com) on the product description page.

Some of the product names, patents, and registered designs referred to in this book are in fact registered trademarks or proprietary names even though specific reference to this fact is not always made in the text. Therefore, the appearance of a name without designation as proprietary is not to be construed as a representation by the publisher that it is in the public domain.

© 2021, Thieme. All rights reserved.

Thieme Medical Publishers, Inc.  
333 Seventh Avenue, 18th Floor  
New York, NY 10001, USA  
[www.thieme.com](http://www.thieme.com)  
+1 800 782 3488, [customerservice@thieme.com](mailto:customerservice@thieme.com)

Cover design: Thieme Publishing Group  
Typesetting by Ditech, India

Printed in USA by King Printing  
Company, Inc.

5 4 3 2 1

ISBN 978-1-62623-494-9  
Also available as e-book:  
eISBN 978-1-62623-495-6

This book, including all parts thereof, is legally protected by copyright. Any use, exploitation, or commercialization outside the narrow limits set by copyright legislation, without the publisher's consent, is illegal and liable to prosecution. This applies in particular to photostat reproduction, copying, mimeographing, preparation of microfilms, and electronic data processing and storage.

# Contents

|   |     |
|---|-----|
| <b>Preface</b>  | xv  |
| <b>Contributors</b>   | xvi |
| <br>  |     |
| <b>1. Encephalopathy and Delirium</b>                                       | 1   |
| <i>Catriona M. Harrop</i>   |     |
| <br>  |     |
| <b>1.1 Encephalopathy</b>   | 1   |
| 1.1.1 Definition  | 1   |
| 1.1.2 Causes of Encephalopathy  | 1   |
| 1.1.3 Diagnosis of Encephalopathy   | 1   |
| 1.1.4 Treatment of Encephalopathy   | 3   |
| 1.1.5 Relationship to Delirium  | 3   |
| <b>1.2 Delirium</b>   | 3   |
| 1.2.1 Definition  | 3   |
| 1.2.2 Duration of Symptoms  | 4   |
| 1.2.3 Level of Activity   | 4   |
| 1.2.4 Risk Factors for Delirium   | 5   |
| 1.2.5 Clinical Assessment   | 5   |
| <b>1.3 Treatment</b>  | 8   |
| 1.3.1 Medications for Agitation   | 8   |
| 1.3.2 Pharmacologic Management of Hyperactive Delirium and Agitation        | 8   |
| 1.3.3 Nonpharmacologic Treatments for Delirium                              | 8   |
| <br>  |     |
| <b>2. Cerebrovascular Emergency: Acute Stroke Diagnosis and Management</b>  | 11  |
| <i>Maria Carissa C. Pineda, Sridhara S. Yaddanapudi, and Norman Ajiboye</i> |     |
| <br>  |     |
| <b>2.1 Epidemiology</b>   | 11  |
| <b>2.2 Etiology</b>   | 11  |
| 2.2.1 Nonmodifiable Risk Factors  | 11  |
| 2.2.2 Modifiable Risk Factors   | 11  |
| 2.2.3 Stroke Subtypes   | 12  |
| <b>2.3 Common Clinical Presentations</b>                                    | 12  |
| <b>2.4 Differential Diagnosis for Acute Ischemic Stroke</b>                 | 12  |

|            |  |    |
|------------|--|----|
| <b>2.5</b> | <b>Acute Stroke Diagnosis, Treatment, and Management</b>                     | 13 |
| 2.5.1      | Stroke Activation  | 13 |
| <b>2.6</b> | <b>Criteria for Endovascular Therapy</b>                                     | 18 |
| 2.6.1      | Neurocritical Care Management of Ischemic Stroke                             | 23 |
| <b>2.7</b> | <b>Stroke Workup and Management</b>  | 26 |
| 2.7.1      | Post Stroke Complication   | 28 |
| <b>3.</b>  | <b>Cerebrovascular Emergency: Spontaneous Intracerebral Hemorrhage (ICH)</b> | 33 |
|            | <i>Syed Omar Shah</i>  |    |
| <b>3.1</b> | <b>Epidemiology</b>  | 33 |
| <b>3.2</b> | <b>Etiologies/Differential Diagnosis</b>                                     | 33 |
| <b>3.3</b> | <b>Common Clinical Presentations</b>   | 34 |
| <b>3.4</b> | <b>Neuroimaging</b>  | 35 |
| <b>3.5</b> | <b>Treatment</b>   | 35 |
| 3.5.1      | Aggressive Reduction in SBP to Goal of 140                                   | 37 |
| 3.5.2      | Seizures   | 37 |
| 3.5.3      | Intracranial Pressure  | 37 |
| 3.5.4      | Medical Issues   | 37 |
| 3.5.5      | Coagulopathies   | 38 |
| 3.5.6      | Surgical Options   | 38 |
| 3.5.7      | Craniotomy   | 38 |
| 3.5.8      | Craniectomy  | 38 |
| 3.5.9      | Minimally Invasive Surgical Evacuation                                       | 40 |
| <b>3.6</b> | <b>Prognosis</b>   | 40 |
| <b>4.</b>  | <b>Cerebrovascular Emergencies: Aneurysmal Subarachnoid Hemorrhage (SAH)</b> | 45 |
|            | <i>Norman Ajiboye, Yu Kan Au, and Syed Omar Shah</i>                         |    |
| <b>4.1</b> | <b>Epidemiology</b>  | 45 |
| <b>4.2</b> | <b>Risk Factors</b>  | 45 |
| <b>4.3</b> | <b>Diagnosis</b>   | 45 |
| <b>4.4</b> | <b>Grading System</b>  | 46 |
| 4.4.1      | Hunt and Hess Grade  | 46 |



|             |  |           |
|-------------|--|-----------|
| 4.4.2       | World Federation of Neurological Surgeons Grade .....  | 47        |
| 4.4.3       | Modified Fischer Scores .....  | 47        |
| <b>4.5</b>  | <b>Management of Subarachnoid Hemorrhage .....</b>   | <b>47</b> |
| 4.5.1       | Early Phase .....  | 48        |
| 4.5.2       | Late Phase .....   | 51        |
| <b>4.6</b>  | <b>Vasospasm, Delayed Neurologic Deterioration (DND), and Delayed Cerebral Ischemia (DCI).....</b> | <b>53</b> |
| 4.6.1       | Detection and Management of Vasospasm and DCI .....  | 54        |
| <b>4.7</b>  | <b>Hyponatremia and Endocrine Dysfunction .....</b>  | <b>56</b> |
| 4.7.1       | Hyponatremia .....   | 56        |
| 4.7.2       | Endocrine Dysfunction .....  | 56        |
| <b>5.</b>   | <b>Transfusion Medicine and Anticoagulation .....</b>  | <b>58</b> |
|             | <i>Bhuvanesh Govind and Matthew Vibbert</i>  |           |
| <b>5.1</b>  | <b>Introduction .....</b>  | <b>58</b> |
| <b>5.2</b>  | <b>Anemia in the ICU.....</b>  | <b>58</b> |
| <b>5.3</b>  | <b>Red Cell Transfusion .....</b>  | <b>59</b> |
| 5.3.1       | Leukocyte Reduction Indications .....  | 59        |
| 5.3.2       | Washed RBC.....  | 59        |
| 5.3.3       | Irradiation.....   | 59        |
| 5.3.4       | Complications of Red Blood Cell Transfusion .....  | 59        |
| 5.3.5       | Benefits to Transfusion .....  | 60        |
| <b>5.4</b>  | <b>Hemoglobin “Triggers” .....</b>   | <b>60</b> |
| <b>5.5</b>  | <b>Thrombocytopenia .....</b>  | <b>61</b> |
| <b>5.6</b>  | <b>Prophylaxis Thresholds .....</b>  | <b>62</b> |
| 5.6.1       | Treatment of Bleeding.....   | 62        |
| <b>5.7</b>  | <b>Antiplatelet Reversal in Intracranial Hemorrhage.....</b>                                       | <b>62</b> |
| <b>5.8</b>  | <b>Coagulation Cascade and Anticoagulants .....</b>  | <b>64</b> |
| <b>5.9</b>  | <b>Anticoagulants.....</b>   | <b>64</b> |
| 5.9.1       | Warfarin .....   | 64        |
| <b>5.10</b> | <b>Oral Factor Xa Inhibitors.....</b>  | <b>66</b> |
| 5.10.1      | Apixaban, Rivaroxaban, Edoxaban.....   | 66        |
| <b>5.11</b> | <b>Thrombin Inhibitors .....</b>   | <b>67</b> |

|             |  |            |
|-------------|--|------------|
| 5.11.1      | Oral.....  | 67         |
| 5.11.2      | Intravenous.....   | 69         |
| <b>5.12</b> | <b>The Heparins.....</b>   | <b>70</b>  |
| 5.12.1      | Unfractionated Heparin .....                                     | 70         |
| 5.12.2      | Low-Molecular-Weight Heparin (LMWH).....                         | 70         |
| 5.12.3      | Fondaparinux.....  | 71         |
| <b>5.13</b> | <b>Deep Vein Thrombosis (DVT) Prophylaxis .....</b>              | <b>72</b>  |
| <b>6.</b>   | <b>Cerebral Edema and Elevated Intracranial Pressure.....</b>    | <b>75</b>  |
|             | <i>Anna Karpenko and Michelle Ghobrial</i>                       |            |
| <b>6.1</b>  | <b>The Basics.....</b>   | <b>75</b>  |
| 6.1.1       | Monro-Kellie Doctrine.....                                       | 75         |
| 6.1.2       | ICP and Cerebral Perfusion Pressure (CPP).....                   | 75         |
| 6.1.3       | Intracranial Compliance .....                                    | 76         |
| 6.1.4       | ICP Waveforms and Herniation Syndromes.....                      | 76         |
| <b>6.2</b>  | <b>Cerebral Edema.....</b>                                       | <b>81</b>  |
| <b>6.3</b>  | <b>Stepwise Approach to the Management of Elevated ICP .....</b> | <b>82</b>  |
| <b>6.4</b>  | <b>Management of Increased Intracranial Pressure .....</b>       | <b>84</b>  |
| 6.4.1       | Tier 1 .....   | 84         |
| 6.4.2       | Tier 2 .....   | 84         |
| 6.4.3       | Tier 3 .....   | 86         |
| <b>7.</b>   | <b>Fevers and Infections in the Neuro-ICU .....</b>              | <b>91</b>  |
|             | <i>Deena M. Athas, Amna Sheikh, and Jacqueline S. Urtecho</i>    |            |
| <b>7.1</b>  | <b>Brain .....</b>   | <b>91</b>  |
| 7.1.1       | Meningitis.....  | 91         |
| 7.1.2       | Acute Bacterial Meningitis .....                                 | 92         |
| 7.1.3       | Aseptic Meningitis .....   | 96         |
| 7.1.4       | Viral Meningitis.....  | 96         |
| 7.1.5       | Fungal Meningitis.....   | 97         |
| 7.1.6       | Ventriculitis .....  | 97         |
| 7.1.7       | HIV-Related Infections.....                                      | 99         |
| 7.1.8       | Empyema .....  | 103        |
| <b>7.2</b>  | <b>Spine.....</b>  | <b>104</b> |
| 7.2.1       | Epidural Abscess .....   | 104        |
| 7.2.2       | Osteomyelitis .....  | 106        |
| <b>7.3</b>  | <b>Central Fever.....</b>  | <b>108</b> |

|  |     |
|--|-----|
| <b>8. Treatment of Status Epilepticus in Adults</b> .....  | 111 |
| <i>James Park, Alan Wang, Andres Fernandez, and Sara Hefton</i>  |     |
| <b>8.1 Overview and Definitions</b> .....  | 111 |
| <b>8.2 Convulsive Status Epilepticus Management</b> .....  | 112 |
| <b>8.3 Nonconvulsive Status Epilepticus (NCSE)</b> .....   | 115 |
| <b>8.4 Refractory Status Epilepticus (RSE)</b> .....   | 116 |
| <b>8.5 Super Refractory Status Epilepticus (SRSE)</b> .....  | 116 |
| <b>9. Trauma</b> .....   | 119 |
| <i>Ravichandra Madineni and Christian Hoelscher</i>  |     |
| <b>9.1 Acute Spinal Cord Injury</b> .....  | 119 |
| 9.1.1 Introduction .....   | 119 |
| 9.1.2 Medical Treatment of Acute SCI .....   | 119 |
| 9.1.3 Surgical Management of Acute SCI .....   | 121 |
| <b>9.2 Traumatic Brain Injury</b> .....  | 122 |
| 9.2.1 Introduction .....   | 122 |
| 9.2.2 Management of Elevated ICP .....   | 125 |
| 9.2.3 Other Post-TBI Considerations .....  | 126 |
| <b>9.3 Paroxysmal Sympathetic Hyperactivity (PSH)</b> .....  | 127 |
| <b>10. Neuromuscular and Other Neurologic Emergencies</b> .....  | 132 |
| <i>Danielle Wilhour and Alison L. Walsh</i>  |     |
| <b>10.1 Guillain-Barré Syndrome (GBS)/Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP)</b> ..... | 132 |
| 10.1.1 Definition .....  | 132 |
| 10.1.2 Epidemiology .....  | 132 |
| 10.1.3 Differential Diagnosis .....  | 133 |
| 10.1.4 Common Clinical Presentation .....  | 133 |
| 10.1.5 Diagnosis .....   | 133 |
| 10.1.6 GBS Variants .....  | 133 |
| 10.1.7 Ancillary Testing .....   | 134 |
| 10.1.8 Complications of GBS .....  | 134 |
| 10.1.9 Management .....  | 135 |
| 10.1.10 Prognosis .....  | 135 |
| <b>10.2 Myasthenia Gravis</b> .....  | 136 |
| 10.2.1 Definition .....  | 136 |

|             |   |            |
|-------------|---|------------|
| 10.2.2      | Epidemiology.....   | 136        |
| 10.2.3      | Differential Diagnosis.....   | 136        |
| 10.2.4      | Clinical Presentation of Generalized Myasthenia Gravis.....   | 136        |
| 10.2.5      | Diagnosis.....  | 137        |
| 10.2.6      | Management of Myasthenic Crisis.....  | 137        |
| 10.2.7      | Prognosis.....  | 138        |
| <b>10.3</b> | <b>Botulism</b> .....   | <b>139</b> |
| 10.3.1      | Definition.....   | 139        |
| 10.3.2      | Epidemiology.....   | 139        |
| 10.3.3      | Pathophysiology.....  | 139        |
| 10.3.4      | Differential Diagnosis.....   | 139        |
| 10.3.5      | Clinical Presentation.....  | 139        |
| 10.3.6      | Diagnosis.....  | 140        |
| 10.3.7      | Management.....   | 140        |
| 10.3.8      | Prognosis.....  | 140        |
| <b>10.4</b> | <b>Organophosphate Toxicity</b> .....   | <b>141</b> |
| 10.4.1      | Definition.....   | 141        |
| 10.4.2      | Epidemiology.....   | 141        |
| 10.4.3      | Pathophysiology.....  | 141        |
| 10.4.4      | Differential Diagnosis.....   | 141        |
| 10.4.5      | Clinical Presentation.....  | 141        |
| 10.4.6      | Diagnosis.....  | 141        |
| 10.4.7      | Management.....   | 142        |
| 10.4.8      | Prognosis.....  | 142        |
| <b>10.5</b> | <b>Neuroleptic Malignant Syndrome (NMS) and Serotonin Syndrome (SS)</b> .....                         | <b>142</b> |
| 10.5.1      | Definition.....   | 142        |
| 10.5.2      | Epidemiology.....   | 143        |
| 10.5.3      | Pathogenesis.....   | 143        |
| 10.5.4      | Differential Diagnosis.....   | 143        |
| 10.5.5      | Clinical Presentation.....  | 143        |
| 10.5.6      | Diagnosis.....  | 143        |
| 10.5.7      | Management.....   | 144        |
| 10.5.8      | Complications.....  | 145        |
| 10.5.9      | Prognosis.....  | 146        |
| <b>11.</b>  | <b>Brain Tumor Postoperative Management</b> .....   | <b>149</b> |
|             | <i>Richard F. Schmidt, Nikolaos Mouchtouris, Muaz Qayyum, James J. Evans, and Christopher Farrell</i> |            |
| <b>11.1</b> | <b>Introduction</b> .....   | <b>149</b> |
| 11.1.1      | Clinical Presentation.....  | 150        |
| 11.1.2      | Tumor Classification.....   | 151        |

|   |     |
|---|-----|
| <b>11.2 Postoperative Care and Complications</b>                        | 152 |
| 11.2.1 Airway Management  | 152 |
| 11.2.2 Blood Pressure Control and Postoperative Hemorrhage              | 156 |
| 11.2.3 Seizure Prophylaxis  | 156 |
| 11.2.4 Venous Thromboembolism Prophylaxis                               | 157 |
| 11.2.5 Antibiotic Prophylaxis and Postoperative Infection               | 158 |
| 11.2.6 Cerebral Edema   | 159 |
| 11.2.7 CSF Leak   | 160 |
| <b>11.3 Specific Concerns for Sellar and Parasellar Tumors</b>          | 162 |
| 11.3.1 Hormonal Dysregulation   | 162 |
| 11.3.2 Pituitary Apoplexy   | 164 |
| <b>11.4 Conclusion</b>  | 165 |
| <b>12. Brain Death in Adults</b>  | 169 |
| <i>Rodney D. Bell, Norman Ajiboye, and Yu Kan Au</i>                    |     |
| 12.1 Definition of Brain Death  | 169 |
| 12.2 Clinical Evaluation  | 169 |
| 12.2.1 Establishing the Proximate Cause of Coma                         | 170 |
| 12.2.2 Clinical Examination to Establish Irreversibility                | 170 |
| 12.3 Ancillary Tests  | 171 |
| 12.4 Legal  | 171 |
| 12.5 Management of the Brain-Dead Patient for Organ Donation            | 172 |
| <b>13. Sodium Dysregulation</b>   | 178 |
| <i>M. Kamran Athar and Christian Bachele</i>                            |     |
| 13.1 Terminology  | 178 |
| 13.2 Hyponatremia Classification  | 178 |
| 13.2.1 Causes of Hyponatremia   | 179 |
| 13.2.2 Symptomatic Hyponatremia   | 179 |
| 13.3 SIADH versus CSW   | 181 |
| 13.3.1 Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) | 181 |
| 13.3.2 Cerebral Salt Wasting (CSW)                                      | 181 |
| 13.3.3 SIADH and CSW Diagnosis  | 182 |
| 13.4 Diagnostic Approach to Hyponatremia                                | 183 |
| 13.4.1 Hyponatremia Treatment: General Principles                       | 184 |

|             |  |            |
|-------------|--|------------|
| 13.4.2      | Acute Symptomatic Moderate to Severe Hyponatremia .....                  | 184        |
| 13.4.3      | Acute Asymptomatic Moderate Hyponatremia .....                           | 185        |
| 13.4.4      | Severe Chronic Mild-Moderate Hyponatremia .....                          | 185        |
| 13.4.5      | SIADH Treatment .....  | 186        |
| 13.4.6      | CSW Treatment .....  | 186        |
| 13.4.7      | Treatment of Hyponatremia in Patients with Subarachnoid Hemorrhage ..... | 186        |
| 13.4.8      | Treatment of Hyponatremia in Patients with Heart Failure .....           | 187        |
| <b>13.5</b> | <b>Hypernatremia .....</b>   | <b>187</b> |
| 13.5.1      | Central (Neurogenic) Diabetes Insipidus .....                            | 187        |
| 13.5.2      | Nephrogenic Diabetes Insipidus .....                                     | 189        |
| <b>13.6</b> | <b>Diagnostic Approach to Hypernatremia .....</b>                        | <b>189</b> |
| 13.6.1      | Treatment .....  | 190        |
| 13.6.2      | Central DI Treatment .....   | 192        |
| 13.6.3      | Nephrogenic DI Treatment .....   | 192        |
| <b>14.</b>  | <b>Nutrition .....</b>   | <b>194</b> |
|             | <i>Stephanie Dobak and Jacqueline S. Urtecho</i>                         |            |
| <b>14.1</b> | <b>Glucose Utilization .....</b>   | <b>194</b> |
| <b>14.2</b> | <b>Nutrition in Critical Care .....</b>                                  | <b>194</b> |
| <b>14.3</b> | <b>Nutrition Status .....</b>  | <b>196</b> |
| 14.3.1      | Malnutrition .....   | 196        |
| 14.3.2      | Refeeding Syndrome .....   | 198        |
| 14.3.3      | Nutrition-Related Laboratory Tests .....                                 | 198        |
| <b>14.4</b> | <b>Nutrition Assessment .....</b>  | <b>198</b> |
| 14.4.1      | Calorie Needs .....  | 198        |
| 14.4.2      | Protein Needs .....  | 199        |
| 14.4.3      | Nutrition Support .....  | 200        |
| 14.4.4      | Enteral Nutrition .....  | 200        |
| <b>14.5</b> | <b>Specific EN Considerations .....</b>                                  | <b>204</b> |
| 14.5.1      | Parenteral Nutrition .....   | 204        |
| <b>14.6</b> | <b>Therapy-Specific Considerations .....</b>                             | <b>204</b> |
| <b>14.7</b> | <b>Conclusion .....</b>  | <b>208</b> |
| <b>15.</b>  | <b>Sedation .....</b>  | <b>210</b> |
|             | <i>Akta Patel and Michelle Ghobrial</i>                                  |            |
| <b>15.1</b> | <b>Introduction .....</b>  | <b>210</b> |

|             |  |     |
|-------------|--|-----|
| <b>15.2</b> | <b>Indications for Sedation</b>  | 210 |
| <b>15.3</b> | <b>Complications of Sedation</b>   | 211 |
| <b>15.4</b> | <b>Assessment of Sedation</b>  | 211 |
| <b>15.5</b> | <b>Choice of Sedative</b>  | 212 |
| 15.5.1      | Propofol (Diprivan)  | 216 |
| 15.5.2      | Midazolam (Versed)   | 217 |
| 15.5.3      | Dexmedetomidine (Precedex)   | 218 |
| 15.5.4      | Fentanyl (Sublimaze)   | 219 |
| 15.5.5      | Ketamine (Ketalar)   | 220 |
| <b>16.</b>  | <b>Pain Management in the Neuro-Intensive Care Unit (ICU)</b>            | 222 |
|             | <i>Amy Shah, David A. Wyler, and Andrew Ng</i>                           |     |
| <b>16.1</b> | <b>Introduction</b>  | 222 |
| <b>16.2</b> | <b>Modern Strategy of Pain Management in ICU Liberation</b>              | 223 |
| <b>16.3</b> | <b>Challenges of Pain Management in Neuro-ICU</b>                        | 224 |
| <b>16.4</b> | <b>Individualizing Therapy in NICU</b>                                   | 224 |
| 16.4.1      | Pharmacologic Interventions of Pain                                      | 224 |
| 16.4.2      | Nonpharmacologic Approach  | 233 |
| <b>16.5</b> | <b>Neuro-specific Diseases at Risk for Pain</b>                          | 233 |
| 16.5.1      | Pain with SAH  | 233 |
| 16.5.2      | Spondylosis and Disk Herniation  | 233 |
| 16.5.3      | Spasticity   | 234 |
| <b>16.6</b> | <b>Ongoing Continuous Pain Monitoring in NICU</b>                        | 234 |
| 16.6.1      | Pain Scales  | 234 |
| <b>17.</b>  | <b>Advanced Hemodynamic and Neurological Monitoring in the Neuro-ICU</b> | 238 |
|             | <i>David F. Slottje and John W. Liang</i>                                |     |
| <b>17.1</b> | <b>Hemodynamic Monitoring</b>  | 238 |
| 17.1.1      | Invasive Monitoring: Pulmonary Thermodilution                            | 240 |
| 17.1.2      | Less Invasive: Transpulmonary Thermodilution                             | 241 |
| 17.1.3      | Minimally Invasive Monitoring: Pulse Contour Analysis                    | 245 |
| 17.1.4      | Noninvasive Hemodynamic Monitoring                                       | 247 |
| <b>17.2</b> | <b>Neurological Monitoring</b>   | 249 |
| 17.2.1      | Noninvasive Monitors   | 249 |

|             |  |     |
|-------------|--|-----|
| 17.2.2      | Invasive Monitors: Cerebral Oximetry .....       | 254 |
| 17.2.3      | Cerebral Blood Flow Monitors. ....               | 260 |
| 17.2.4      | Intracranial Pressure Monitoring .....           | 261 |
| <b>18.</b>  | <b>Neuroimaging</b> .....                        | 266 |
|             | <i>Michael J. Lang</i>                           |     |
| <b>18.1</b> | <b>Introduction</b> .....                        | 266 |
| <b>18.2</b> | <b>Types of Imaging</b> .....                    | 266 |
| 18.2.1      | Brain Imaging. ....                              | 266 |
| 18.2.2      | Spine Imaging .....                              | 266 |
| <b>18.3</b> | <b>Advantages and Limitations</b> .....          | 267 |
| 18.3.1      | Brain Imaging. ....                              | 267 |
| 18.3.2      | Spine Imaging .....                              | 279 |
| 18.3.3      | Systemic. ....                                   | 281 |
| <b>19.</b>  | <b>Ventilation Strategies in Neuro-ICU</b> ..... | 285 |
|             | <i>Amandeep S. Dolla and M. Kamran Athar</i>     |     |
| <b>19.1</b> | <b>Introduction</b> .....                        | 285 |
| <b>19.2</b> | <b>Respiratory Failure</b> .....                 | 285 |
| 19.2.1      | Noninvasive Oxygenation and Ventilation. ....    | 285 |
| 19.2.2      | Invasive Mechanical Ventilation. ....            | 289 |
| 19.2.3      | Basic Principles of Mechanical Ventilation ..... | 291 |
| 19.2.4      | Modes of Ventilation .....                       | 292 |
| 19.2.5      | Initial Ventilator Settings .....                | 294 |
| 19.2.6      | For Pressure Ventilation .....                   | 295 |
| 19.2.7      | Common Ventilator Problems. ....                 | 295 |
| 19.2.8      | Weaning from Ventilator .....                    | 295 |
| 19.2.9      | WHEANS NOT Mnemonic. ....                        | 295 |
| 19.2.10     | Extubation Procedure .....                       | 297 |
|             | <b>Index</b> .....                               | 299 |



---

## Preface

*Everything we do, every thought we've ever had, is produced by the brain. But exactly how it operates remains one of the biggest unsolved mysteries, and it seems the more we probe its secrets, the more surprises we find.*

*Neil deGrasse Tyson*

This book was developed out of a desire to share our knowledge and experience in neurocritical care from Thomas Jefferson University Hospitals. The brain continues to be a “black box” for many practitioners and the need for expertise is greater than ever in this evolving field. As a large quaternary hospital with 40 dedicated neurocritical care beds and 8 board-certified neurointensivists, we have extensive experience with both common and rare neurological and neurosurgical diseases (ischemic stroke, intracerebral hemorrhage,

subarachnoid hemorrhage, acute spinal cord injury, traumatic brain injury, encephalitis/meningitis, myasthenia gravis, Guillain-Barré syndrome). Using current guidelines and Thomas Jefferson University protocols, we map out a process for the diagnosis and treatment of the more common diseases managed in the neuro-ICU. We chose a format that would be user-friendly so that any practitioner could use at the bedside. As we continue to discover more of the brain's secrets and advance the field of neurocritical care, we will continue to update this handbook.

We would like to acknowledge and thank all the contributors to this book. Without their dedication and hard work, this book wouldn't have been possible.

*Jack I. Jallo, MD, PhD  
Jacqueline S. Urtecho, MD*

---

# Contributors

**Norman Ajiboye, MD**

Assistant Professor of Neuroendovascular  
Surgery  
Department of Surgery  
Texas Christian University  
University of North Texas School of Medicine  
Dallas-Fort Worth, Texas USA;  
Co-Medical Director  
Neuroendovascular Surgery Fellowship,  
Texas Stroke Institute  
Dallas, Texas, USA

**M. Kamran Athar, MD**

Assistant Professor of Medicine and  
Neurological Surgery  
Department of Neurological Surgery  
Division of Neuro-Trauma and Critical Care  
Sidney Kimmel Medical College  
Thomas Jefferson University  
Philadelphia, Pennsylvania, USA

**Deena M. Athas, MD**

Infectious Disease Specialist  
Gundersen Health System  
La Crosse, Wisconsin, USA

**Yu Kan Au, MD**

Assistant Professor of Neurology  
University of Connecticut  
Hartford, Connecticut, USA

**Christian Bachele, MD**

Neurohospitalist, Vascular Neurologist  
Memorial Healthcare System  
Hollywood, Florida, USA

**Rodney D. Bell, MD**

Professor of Neurology  
Lynne and Harold Honickman  
Vice Chairman (Hospital Affairs)  
Department of Neurology  
Sidney Kimmel Medical College  
Thomas Jefferson University  
Philadelphia, Pennsylvania, USA

**Stephanie Dobak, MS, RD, LDN, CNSC**

Clinical Dietitian III  
Jefferson Weinberg ALS Center  
Philadelphia, Pennsylvania, USA

**Amandeep S. Dolla, MBBS, MD**

Clinical Assistant Professor  
Department of Neurology/Division of  
Neurocritical Care  
Sidney Kimmel Medical College  
Thomas Jefferson University  
Philadelphia, Pennsylvania, USA

**James J. Evans, MD**

Professor of Neurological Surgery and  
Otolaryngology  
Department of Neurological Surgery  
Sidney Kimmel Medical College  
Thomas Jefferson University  
Philadelphia, Pennsylvania, USA

**Christopher Farrell, MD**

Assistant Professor  
Department of Neurological Surgery  
Sidney Kimmel Medical College  
Thomas Jefferson University  
Philadelphia, Pennsylvania, USA

**Andres Fernandez, MD, MSc**

Assistant Professor  
Department of Neurology  
Sidney Kimmel Medical College  
Thomas Jefferson University  
Philadelphia, Pennsylvania, USA

**Michelle Ghobrial, MD**

Neurointensivist  
Novant Health  
Winston Salem, North Carolina, USA

**Bhuvanesh Govind, MD**

Staff Neurointensivist  
Medical City Plano  
Plano, Texas, USA

**Catriona M. Harrop, MD, SFHM, FACP**  
 Associate Chief Medical Officer, South  
 Philadelphia  
 Medical Co-Director for Pre Admission  
 Testing  
 Associate Professor of Clinical Medicine  
 Sidney Kimmel Medical College  
 Thomas Jefferson University  
 Philadelphia, Pennsylvania, USA

**Sara Hefton, MD**  
 Assistant Professor of Neurology and  
 Neurological Surgery  
 Department of Neurological Surgery  
 Division of Neurotrauma and Critical Care  
 Sidney Kimmel Medical College  
 Thomas Jefferson University  
 Philadelphia, Pennsylvania, USA

**Christian Hoelscher, MD**  
 Clinical Assistant Professor of Neurosurgery  
 Sidney Kimmel Medical College  
 Thomas Jefferson University  
 Philadelphia, Pennsylvania, USA

**Anna Karpenko, MD**  
 Assistant Professor  
 Department of Neurology  
 Dartmouth Hitchcock Medical Center  
 Lebanon, New Hampshire, USA

**Michael J. Lang, MD**  
 Assistant Professor  
 Department of Neurosurgery  
 University of Pittsburgh Medical Center  
 Pittsburgh, Pennsylvania, USA

**John W. Liang, MD**  
 Director  
 Neurosciences ICU  
 Mount Sinai West;  
 Assistant Professor  
 Departments of Neurosurgery & Neurology  
 Mount Sinai Health System  
 New York, New York, USA

**Ravichandra Madineni, MD**  
 Neurosurgeon  
 Main Line Health Jefferson Neurosurgery  
 Bryn Mawr Hospital  
 Bryn Mawr, Pennsylvania, USA

**Nikolaos Mouchtouris, MD**  
 Resident Physician in Neurological Surgery  
 Sidney Kimmel Medical College  
 Thomas Jefferson University  
 Philadelphia, Pennsylvania, USA

**Andrew Ng, MD**  
 Assistant Professor of Anesthesiology and  
 Physical Medicine and Rehabilitation  
 Program Director Pain Medicine Fellowship  
 Department of Anesthesiology, Jefferson Pain  
 Center  
 Thomas Jefferson University  
 Philadelphia, Pennsylvania, USA

**James Park, DO**  
 Epileptologist  
 Pickup Family Neuroscience Institute  
 Hoag Hospital  
 Newport Beach/Irvine, California, USA

**Akta Patel, PharmD, BCPS**  
 Advanced Practice Pharmacist, Critical Care  
 Department of Pharmacy  
 Thomas Jefferson University  
 Philadelphia, Pennsylvania, USA

**Maria Carissa C. Pineda, MD**  
 Associate Professor  
 Department of Neurosciences  
 University of the Philippines  
 Manila, Philippines

**Muaz Qayyum, MBBS**  
 Research Fellow  
 Department of Neurological Surgery  
 Sidney Kimmel Medical College  
 Thomas Jefferson University  
 Philadelphia, Pennsylvania, USA

**Richard F. Schmidt, MD**

Clinical Assistant Professor  
Department of Neurological Surgery  
Sidney Kimmel Medical College  
Thomas Jefferson University  
Philadelphia, Pennsylvania, USA

**Amy Shah, MD**

Physician Neurosurgical Anesthesiologist  
Valley Anesthesiology Consultants  
Envision Physician Services  
Phoenix, Arizona, USA

**Syed Omar Shah, MD, MBA**

Assistant Professor of Neurology and  
Neurological Surgery  
Associate Fellowship Director,  
Neurocritical Care  
Department of Neurological Surgery  
Sidney Kimmel Medical College  
Thomas Jefferson University  
Philadelphia, Pennsylvania, USA

**Amna Sheikh, MBBS, MD**

Intensivist  
Department of Critical Care  
Winchester Medical Center  
Winchester, Virginia, USA

**David F. Slottje, MD**

Neurosurgeon  
Sentara Martha Jefferson Neurosciences  
Charlottesville, Virginia, USA

**Jacqueline S. Urtecho, MD**

Assistant Professor of Neurology and  
Neurological Surgery  
Department of Neurological Surgery  
Division of Neurotrauma and Critical Care  
Sidney Kimmel Medical College  
Thomas Jefferson University  
Philadelphia, Pennsylvania, USA

**Matthew Vibbert, MD**

Assistant Professor  
Neurology and Neurological Surgery;  
Director, Neurocritical Care  
Sidney Kimmel Medical College  
Thomas Jefferson University  
Philadelphia, Pennsylvania, USA

**Alison L. Walsh, MD**

Assistant Professor  
Morsani College of Medicine  
University of South Florida  
Tampa, Florida, USA;  
Division of Neurology  
Lehigh Valley Health Network  
Allentown, Pennsylvania, USA

**Alan Wang, MD**

Clinical Assistant Professor of Neurology  
Department of Neurology  
University of Arizona College of Medicine –  
Phoenix  
Phoenix, Arizona, USA

**Danielle Wilhour, MD**

Assistant Professor  
Department of Neurology  
University of Colorado  
Aurora, Colorado, USA

**David A. Wyler, MD**

Assistant Professor  
Anesthesiology and Neurological Surgery  
Director of Anesthesiology Neurocritical Care  
Assistant Program Director  
Anesthesiology Residency Program  
Sidney Kimmel Medical College  
Thomas Jefferson University  
Philadelphia, Pennsylvania, USA

**Sridhara S. Yaddanapudi, MBBS, MD**

Neurohospitalist  
ChristianaCare Medical Center  
Newark, Delaware, USA

# 1 Encephalopathy and Delirium

Catriona M. Harrop

## Abstract

Encephalopathy is characterized by the National Institute of Neurological Disorders and Stroke as “any diffuse disease of the brain that alters brain function or structure,”<sup>1</sup> and can be classified as acute or chronic. The definition, diagnosis, and treatment of encephalopathy is reviewed here, along with one of its most common symptoms, delirium.

**Keywords:** encephalopathy, delirium, confusion, agitation, arousability, Ramsay score, Riker score

## 1.1 Encephalopathy

### 1.1.1 Definition

The National Institute of Neurological Disorders and Stroke (NINDS) defines encephalopathy as “a term for any diffuse disease of the brain that alters brain function or structure”<sup>1</sup> with the hallmark of encephalopathy being an altered mental state. Encephalopathy can be categorized by chronicity<sup>2</sup>:

- Acute
  - Toxic: due to medications, illicit substances, or toxins
  - Metabolic: due to a metabolic disturbance
  - Toxic-metabolic: due to a combination of both
- Chronic: characterized by a slowly progressive alteration in mental status resulting from permanent structural changes within the brain<sup>2</sup>

### 1.1.2 Causes of Encephalopathy<sup>3</sup>

See ► Table 1.1.

### 1.1.3 Diagnosis of Encephalopathy

Diagnosis is guided by the history and physical examination of the patient. It is considered on a case-by-case basis.

- Laboratory testing
  - Serum electrolytes
  - Renal function
  - Glucose

- Calcium
- Complete blood count
- Urinalysis
- Hepatic function
- Thyroid function
- Drug levels (if applicable), i.e., phenytoin
- Drugs of abuse screen
- Vitamin levels—B-12, folate
- Arterial blood gas
- Imaging
  - Computed tomography (CT) of brain
  - Magnetic resonance imaging (MRI) of brain

| Table 1.1 Common causes of encephalopathy  |   |
|--|---|
| Drugs and toxins                           | Idiopathic<br>Withdrawal states<br>Medication side effects<br>Poisons   |
| Infections                                 | Sepsis<br>Systemic infections<br>Fever  |
| Metabolic derangements                     | Electrolytes<br>Endocrine disturbance<br>Hypercarbia<br>Hyperglycemia and hypoglycemia<br>Hyperosmolar and hypo-osmolar states<br>Hypoxemia<br>Inborn errors of metabolism<br>Nutritional |
| Brain disorders                            | CNS infection<br>Seizures<br>Head injury<br>Hypertensive encephalopathy<br>Psychiatric disorders  |
| Systemic organ failure                     | Cardiac failure<br>Hematologic<br>Hepatic encephalopathy<br>Pulmonary disease<br>Renal failure  |
| Abbreviation: CNS, central nervous system. |   |

- Evaluation for infections
  - Lumbar puncture
  - Blood cultures
- Seizure evaluation
  - Electroencephalography (EEG)

### 1.1.4 Treatment of Encephalopathy

- Acute encephalopathy
  - Based on treatment of the underlying pathophysiology, i.e., treatment of sepsis and hypothyroidism with the potential for reversal of encephalopathy.
- Chronic encephalopathy
  - Often not amenable to treatment as the inciting insult has caused permanent brain changes, i.e., anoxic encephalopathy.

### 1.1.5 Relationship to Delirium

Delirium can be characterized as the symptom of the underlying abnormal brain function, i.e., encephalopathy.<sup>2</sup>

## 1.2 Delirium

Delirium is a common disorder in hospitalized patients that has significant societal and economic impact.<sup>4</sup> In-hospital mortality rates reportedly associated with delirium range from 22 to 33%.<sup>5,6</sup> Currently patients aged 65 years and older account for more than 48% of hospital care; therefore, the impact of delirium on hospitalized patients will continue to grow as our population ages.<sup>4</sup>

### 1.2.1 Definition

The Diagnostic and Statistical Manual of Mental Disorders (DSM) 5 defines delirium under Neurocognitive Disorders<sup>7</sup> which encompasses “the group of disorders in which the primary clinical deficit is in cognitive function, and that are acquired rather than developmental.” The diagnostic criteria are as follows:

- A disturbance in attention (i.e., reduced ability to direct, focus, sustain, and shift attention) and awareness (reduced orientation to the environment).
- The disturbance develops over a short period of time (usually from hours to a few days), represents a change from baseline attention and awareness, and tends to fluctuate in severity during the course of a day.
- An additional disturbance in cognition (e.g., memory deficit, disorientation, language, visuospatial ability, or perception).

- The disturbances are not explained by another pre-existing, established, or evolving neurocognitive disorder and do not occur in the context of a severely reduced level of arousal, such as coma.
- There is evidence from the history, physical examination, or laboratory findings that the disturbance is a direct physiologic consequence of another medical condition, substance intoxication or withdrawal (i.e., due to a drug of abuse or a medication), or exposure to a toxin, or is due to multiple etiologies.

As outlined in the DSM 5, Delirium can be further subdivided into:

- Substance intoxication
- Substance withdrawal
- Medication induced
- Another medical condition
- Multiple etiologies

### 1.2.2 Duration of Symptoms

- **Acute:** Lasting for a few hours or days
- **Persistent:** Lasting for weeks or months

### 1.2.3 Level of Activity (► Table 1.2)

- **Hyperactive:** The individual has a hyperactive level of psychomotor activity that may be accompanied by mood lability, agitation, and/or refusal to cooperate with medical care.
- **Hypoactive:** The individual has a hypoactive level of psychomotor activity that may be accompanied by sluggishness and lethargy that approaches stupor.
- **Mixed level of activity:** The individual has a normal level of psychomotor activity even though attention and awareness are disturbed. Also includes individuals whose activity level rapidly fluctuates.

Table 1.2 Types of delirium

|             | Description                                  | RASS score | Prevalence <sup>8</sup> |
|-------------|--|------------|-------------------------|
| Hyperactive | Agitation and restlessness                   | 1 + to 4 + | Rare (1.6%)             |
| Hypoactive  | Decreased responsiveness, withdrawal, apathy | 0 to 3     | Common in ICU (43.5%)   |

Abbreviations: ICU, intensive care unit; RASS, Richmond Agitation Sedation Scale.



**Table 1.3** Risk factors for delirium

| Predisposing factors <sup>10</sup>  | Precipitating factors <sup>11</sup>  | Targeted interventions <sup>12</sup>   |
|---|--|--|
| <ul style="list-style-type: none"> <li>• Cognitive impairment</li> <li>• Severe underlying illness</li> <li>• Advanced age</li> <li>• Functional impairment</li> <li>• Chronic renal insufficiency</li> <li>• Dehydration</li> <li>• Malnutrition</li> <li>• Depression</li> <li>• Substance abuse</li> <li>• Vision or hearing impairment</li> </ul> | <ul style="list-style-type: none"> <li>• Use of physical restraints</li> <li>• Malnutrition</li> <li>• More than three medications</li> <li>• Use of bladder catheter</li> <li>• Psychoactive medication use</li> <li>• Any iatrogenic event</li> <li>• Immobilization</li> <li>• Dehydration</li> </ul> | <ul style="list-style-type: none"> <li>• Noise reduction</li> <li>• Reality orientation program</li> <li>• Early mobilization</li> <li>• Minimize medications</li> <li>• Provision of visual and hearing aids</li> <li>• Volume repletion and proper nutrition</li> <li>• Optimize nonpharmacologic protocols</li> </ul> |

A description of a patient in terms of the DSM 5 criteria could look like “acute, hypoactive delirium due to sepsis.”

### 1.2.4 Risk Factors for Delirium

Delirium involves a multifactorial etiology ranging from patient vulnerability to delirium at the time of admission and the occurrence of noxious insults during hospitalization.<sup>9</sup> See ► Table 1.3.

### 1.2.5 Clinical Assessment

Assessment begins in the intensive care unit (ICU) setting for the level of arousability, ranging from sedation to agitation, prior to assessing level of consciousness and subsequent delirium.<sup>13</sup>

### Arousability Assessment Tools

- **Richmond Agitation Sedation Scale (RASS):** See ► Table 1.4. A 10-point scale ranging from +4 to −5, created to assess sedation and agitation in the adult patient admitted to the ICU. An RASS score of 0 denotes a calm and alert patient. Positive RASS scores indicate positive or aggressive symptoms. Negative RASS scores differentiate between response to verbal commands (−1 to −3) and physical stimulus (−4 to −5).<sup>3</sup>
- **Ramsay score:** See ► Table 1.5. It defines the conscious state from a level 1: the patient is anxious, agitated, or restless, through to the continuously sedated level 6: the patient is completely unresponsive.<sup>14</sup>
- **Riker Sedation Agitation Scale (SAS):** See ► Table 1.6. It was developed in 1999 with the goal of clearly defining and providing more inclusive levels of sedation and agitation than the Ramsay score.<sup>15</sup>

| Table 1.4 Richmond Agitation Sedation Scale |  |
|---|--|
| Richmond Agitation Sedation Scale           | Description  |
| + 4 Combative                               | Overtly combative, violent, danger to staff  |
| + 3 Very agitated                           | Pulls or removes tubes or catheters; aggressive  |
| + 3 Agitated                                | Frequent nonpurposeful movement, fights ventilator                                       |
| + 1 Restless                                | Anxious, but movements not aggressive or vigorous  |
| 0 Alert and calm                            |  |
| -1 Drowsy                                   | Not fully alert, but has sustained awakening (eye opening/eye contact) to voice (> 10 s) |
| -2 Light sedation                           | Briefly awakens with eye contact to voice (< 10 s)                                       |
| -3 Moderate sedation                        | Movement or eye opening to voice (but no eye contact)                                    |
| -4 Deep sedation                            | No response to voice, but movement or eye opening to physical stimulation                |
| -5 Unable to rouse                          | No response to voice or physical stimulus  |

| Table 1.5 Ramsay Sedation Scale |  |
|---------------------------------|--|
| Ramsay Sedation Scale           | Description  |
| 1                               | Anxious, agitated, restless  |
| 2                               | Cooperative, oriented, tranquil                                    |
| 3                               | Responsive to commands only  |
| 4                               | Brisk response to light glabellar tap or loud auditory stimulus    |
| 5                               | Sluggish response to light glabellar tap or loud auditory stimulus |
| 6                               | No response to light glabellar tap or loud auditory stimulus       |


Delirium Assessment

Confusion Assessment Method for the ICU (CAM-ICU): See ► Fig. 1.1. Four features assess fluctuation in mental status, inattention, disorganized thinking, and altered level of consciousness.<sup>16</sup>

Table 1.6 Riker Sedation Scale

| Riker Sedation Agitation Scale | Description   |
|--------------------------------|---|
| 7 Dangerous agitation          | Pulling at ET tube, trying to remove catheters, climbing over bedrail, striking at staff, thrashing side to side  |
| 6 Very agitated                | Requiring restraint and frequent verbal reminding of limits, biting ET tube                                       |
| 5 Agitated                     | Anxious or physically agitated, calms to verbal instruction   |
| 4 Calm and cooperative         | Calm, easily arousable, follows commands  |
| 3 Sedated                      | Difficult to arouse but awakens to verbal stimuli or gentle shaking, follows simple commands but drifts off again |
| 2 Very sedated                 | Arouses to physical stimuli but does not communicate or follow commands, may move spontaneously                   |
| 1 Unarousable                  | Minimal to no response to noxious stimuli, does not communicate or follow commands                                |

Abbreviation: ET, endotracheal.



**Fig. 1.1** Confusion assessment method for the intensive care unit (CAM-ICU) flowsheet. Copyright © 2002, E. Wesley Ely, MD, MPH and Vanderbilt University, all rights reserved.

| Table 1.7 Medications used to treat agitation |                                     |   |  |
|---|-------------------------------------|---|--|
| Agent   | Mechanism                           | Advantage   | Adverse effects  |
| Midazolam                                     | Increases GABA activity             | Rapid onset of action with high metabolic clearance             | Respiratory depression, hypotension  |
| Lorazepam                                     | Increases GABA activity             | Intermediate onset of action with mid-range metabolic clearance | Respiratory depression, hypotension; propylene glycol-related acidosis, nephrotoxicity   |
| Diazepam                                      | Increases GABA activity             | Rapid onset of action with long half-life (10–20 hours)         | Respiratory depression, hypotension, phlebitis   |
| Propofol                                      | Increases GABA activity             | Rapid onset of action with high metabolic clearance             | Pain on injection, hypotension, respiratory depression, hypertriglyceridemia, pancreatitis, allergic reactions, propofol infusion syndrome |
| Dexmedetomidine                               | Alpha 2 adrenergic receptor agonist | Provides sedation without respiratory depression risk           | Bradycardia, hypotension; hypertension with loading dose; loss of airway reflexes  |
| Abbreviation: GABA, gamma aminobutyric acid.  |                                     |   |  |

1.3 Treatment

1.3.1 Medications for Agitation<sup>3</sup>

See ► Table 1.7.

1.3.2 Pharmacologic Management of Hyperactive Delirium and Agitation

See ► Table 1.8

1.3.3 Nonpharmacologic Treatments for Delirium<sup>21</sup>

- Frequent reorientation with signs, clocks, and calendars
- Address dehydration and constipation
- Assess for hypoxia and optimize oxygen saturation
- Assess for underlying infection
- Avoid unnecessary catheterization
- Early mobilization

- Address pain
- Review medications
- Nutrition assessment
- Address reversible sensory impairment with glasses and hearing aids
- Promote good sleep hygiene

Table 1.8 Medications used to treat delirium

|  | Mechanism   | Advantage  | Adverse effects   |
|--|---|--|---|
| <b>Typical antipsychotics</b><br>Haloperidol<br>Chlorpromazine<br>Thioridazine           | Postsynaptic blockade of dopamine D2 receptors with varying effect on neuronal 5-HT <sub>2a</sub> , alpha-1, histaminic, and muscarinic receptors <sup>17</sup>   | Fewer anticholinergic effects, few active metabolites, minimally sedating, amelioration of hallucinations, delusion, and unstructured thought patterns <sup>18</sup> | Significant risk of extrapyramidal side effects and tardive dyskinesia; cognitive numbness and dysphoria, extrapyramidal side effects, neuroleptic malignant syndrome, dystonic reactions, ventricular arrhythmias, torsades de pointe, cardiac arrest, QT prolongation <sup>17</sup>                         |
| <b>Atypical antipsychotics</b><br>Olanzapine<br>Risperidone<br>Quetiapine<br>Ziprasidone | Postsynaptic blockade of D2 receptors with varying effect on neuronal 5-HT <sub>2a</sub> , alpha-1, histaminic, and muscarinic receptors; <i>serotonin 5-HT<sub>2</sub> receptor binding exceeds its loose affinity for dopamine D2</i> | Generally they have lower risk of extrapyramidal side effects and tardive dyskinesia compared with first-generation antipsychotics <sup>19</sup>                     | Weight gain and related metabolic effects, hypotension, sedation, anticholinergic symptoms, hyperprolactinemia, extrapyramidal symptoms (EPS), cardiac effects, cardiomyopathies, cataracts, and sexual dysfunction; <i>anticholinergic effects most prominent with olanzapine, quetiapine, and clozapine</i> |
| <b>Benzodiazepines</b><br>Midazolam<br>Lorazepam<br>Diazepam                             | Bind to specific receptors in the gamma aminobutyric acid (GABA) receptor complex, which enhances the binding of this   | Anxiolysis is achieved at low doses; rapid effect; duration varies and can be given via continuous infusion for stability  | Sedation, respiratory and cardiovascular depression; <i>paradoxical reaction characterized by agitation, restlessness, and hostility</i> <sup>20</sup>  |

## References

- [1] Encephalopathy Information Page | National Institute of Neurological Disorders and Stroke. <https://www.ninds.nih.gov/Disorders/All-Disorders/Encephalopathy-Information-Page>. Published 2018. Accessed
- [2] Pinson, R. Encephalopathy: Clinicians often struggle with the distinction between delirium and encephalopathy. Coding Corner, 2015. <https://acphospitalist.org/archives/2015/01/coding.htm>
- [3] Barr J, Fraser GL, Puntillo K, et al. American College of Critical Care Medicine. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. *Crit Care Med*. 2013; 41(1):263–306
- [4] Leslie DL, Marcantonio ER, Zhang Y, Leo-Summers L, Inouye SK. One-year health care costs associated with delirium in the elderly population. *Arch Intern Med*. 2008; 168(1):27–32
- [5] Pandharipande P, Jackson J, Ely EW. Delirium: acute cognitive dysfunction in the critically ill. *Curr Opin Crit Care*. 2005; 11(4):360–368
- [6] Inouye SK, Schlesinger MJ, Lydon TJ. Delirium: a symptom of how hospital care is failing older persons and a window to improve quality of hospital care. *Am J Med*. 1999; 106(5):565–573
- [7] Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. <https://dsm.psychiatryonline.org/doi/book/10.1176/appi.books.9780890425596>
- [8] Peterson JF, Pun BT, Dittus RS, et al. Delirium and its motoric subtypes: a study of 614 critically ill patients. *J Am Geriatr Soc*. 2006; 54(3):479–484
- [9] Inouye SK. Prevention of delirium in hospitalized older patients: risk factors and targeted intervention strategies. *Ann Med*. 2000; 32(4):257–263
- [10] Dubois MJ, Bergeron N, Dumont M, Dial S, Skrobik Y. Delirium in an intensive care unit: a study of risk factors. *Intensive Care Med*. 2001; 27(8):1297–1304
- [11] Girard TD, Pandharipande PP, Ely EW. Delirium in the intensive care unit. *Crit Care*. 2008; 12 Suppl 3:S3
- [12] Elie M, Cole MG, Primeau FJ, Bellavance F. Delirium risk factors in elderly hospitalized patients. *J Gen Intern Med*. 1998; 13(3):204–212
- [13] Khan BA, Guzman O, Campbell NL, et al. Comparison and agreement between the Richmond agitation-sedation scale and the Riker sedation-agitation scale in evaluating patients' eligibility for delirium assessment in the ICU. *Chest*. 2012; 142(1):48–54
- [14] Ramsay MA, Savege TM, Simpson BR, Goodwin R. Controlled sedation with alphaxalone-alphadolone. *BMJ*. 1974; 2(5920):656–659
- [15] Jacobi J, Fraser GL, Coursin DB, et al. Task Force of the American College of Critical Care Medicine (ACCM), of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists (ASHP), American College of Chest Physicians. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. *Crit Care Med*. 2002; 30(1):119–141
- [16] Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegel AP, Horwitz RI. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. *Ann Intern Med*. 1990; 113(12):941–948
- [17] Skrobik YK, Bergeron N, Dumont M, Gottfried SB. Olanzapine vs haloperidol: treating delirium in a critical care setting. *Intensive Care Med*. 2004; 30(3):444–449
- [18] Kalisvaart KJ, de Jonghe JF, Bogaards MJ, et al. Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study. *J Am Geriatr Soc*. 2005; 53(10):1658–1666
- [19] Schwartz TL, Masand PS. The role of atypical antipsychotics in the treatment of delirium. *Psychosomatics*. 2002; 43(3):171–174
- [20] Pandharipande P, Shintani A, Peterson J, et al. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. *Anesthesiology*. 2006; 104(1):21–26
- [21] O'Mahony R, Murthy L, Akunne A, Young J, Guideline Development Group. Synopsis of the National Institute for Health and Clinical Excellence guideline for prevention of delirium. *Ann Intern Med*. 2011; 154(11):746–751

---

## 2 Cerebrovascular Emergency: Acute Stroke Diagnosis and Management

*Maria Carissa C. Pineda, Sridhara S. Yaddanapudi, and Norman Ajiboye*

### **Abstract**

Stroke is one of the leading causes of disability in the USA. Timely acute interventions in the form of tPA and endovascular therapy have changed the landscape of acute stroke care. Having an organized and efficient system of care is extremely important for delivering acute stroke care. This chapter details the components of acute stroke care from the emergency room to the neurocritical care unit. The chapter covers pre- and post-tPA and endovascular care as well as post stroke complication management in the neurocritical care unit.

**Keywords:** acute stroke, tPA, endovascular therapy, neurocritical care

### 2.1 Epidemiology

- Stroke is the fifth leading cause of death in North America
- It is the leading cause of disability
- 795,000 people/year have a stroke in North America

### 2.2 Etiology

#### 2.2.1 Nonmodifiable Risk Factors

- Age
- Sex
- Race
- Family history

#### 2.2.2 Modifiable Risk Factors

- Hypertension
- Diabetes mellitus
- Hyperlipidemia
- Smoking
- Excessive alcohol use
- Obstructive sleep apnea

### 2.2.3 Stroke Subtypes

According to TOAST<sup>9</sup> classification there are five subtypes of ischemic stroke:

1. Large artery atherosclerosis
2. Cardioembolism
3. Small vessel occlusion (lacunar stroke)
4. Stroke of other determined etiology
  - Mechanical valves
  - Atrial fibrillation/flutter
  - Left atrial (LA) appendage thrombus
  - Left ventricular (LV) thrombus
  - Recent myocardial infarction (MI)
  - Dilated cardiomyopathy
  - Endocarditis/infection
  - Patent foramen ovale
  - Atrial septal aneurysm
  - Congestive heart failure
  - Vasculopathies
  - Hypercoagulable state
5. Stroke of undetermined etiology/cryptogenic

### 2.3 Common Clinical Presentations

Presentation depends on the vascular territory. See ► Table 2.1.

F.A.S.T. is the acronym most associated with recognition of early stroke signs:

F = Facial weakness

A = Arm weakness

S = Speech difficulty

T = Time to call 9–1–1

Once in the emergency department a more thorough examination using the National Institutes of Health Stroke Scale (NIHSS) is completed (► Table 2.2).

### 2.4 Differential Diagnosis for Acute Ischemic Stroke

- Intracerebral hemorrhage (ICH)
- Subarachnoid hemorrhage (SAH)
- Migraine with aura (most auras DO NOT last beyond 60 minutes nor present with loss of function)
- Transient global amnesia
- Postictal Todd's palsy (history of epilepsy or prior Todd's palsy, short duration with improvement)
- Hypoglycemia (rapid improvement with glucose correction)<sup>2</sup>



**Table 2.1** Common clinical presentation by vascular territory

| Vascular territory        | Symptoms   |
|---------------------------|--|
| Middle cerebral artery    | Contralateral facial droop, weakness and sensory loss (arm > leg), aphasia, neglect, contralateral homonymous hemianopia, ipsilateral gaze deviation                                   |
| Anterior cerebral artery  | Contralateral hemiplegia (leg >> face and arm), abulia, rigidity, gait apraxia, urinary incontinence   |
| Posterior cerebral artery | Contralateral homonymous hemianopia, alexia, contralateral sensory loss, cortical blindness, visual hallucinations, optic ataxia, gaze apraxia   |
| Subcortical               | Contralateral hemiplegia or hemisensory loss (usually face = arm = leg), no cortical features (aphasia, neglect), thalamic strokes may have aphasia, delirium, other cortical features |
| Basilar artery            | Cranial nerve palsy, crossed sensory deficits, dizziness, diplopia, dysarthria, dysphagia, vertigo, nausea/vomiting, hiccups, contralateral weakness, ataxia, nystagmus, coma          |

## 2.5 Acute Stroke Diagnosis, Treatment, and Management<sup>4</sup>

### 2.5.1 Stroke Activation (► Fig. 2.1)

- **ABC:** airway, breathing, circulation
  - O<sub>2</sub> saturation > 94% (supplemental oxygen is not recommended if the patient is not hypoxic)
  - Finger-stick glucose should be > 50
- Intravenous (IV) access
- **History:** Past medical, surgical, and medication (ask about antiplatelet and anticoagulant agents)
- Check electrocardiogram (ECG)—rule out acute ST-elevation myocardial infarction (STEMI)
- **Send STAT labs:** Coagulation panel and platelet
- Perform focal stroke examination using NIHSS (► Table 2.2 shows the pictures and sentences used for questions 9 and 10 on the scale.)